✕

Aktion bei unserem Broker – nur bis 31. Juli

Von den Profis lernen. Beim Kostensieger handeln.

Handle ab 0 € Ordergebühr (zzgl. Spreads) beim Kostensieger der Stiftung Warentest (12/2025)

Erhalte gratis Zugang zum aktien-Magazin von TraderFox – den „NVIDIA-Entdeckern“ (Wert: 147 €)

Sichere dir zusätzlich 50 € Neukundenbonus direkt auf dein Cash-Konto

Nicht mehr anzeigen

Hofseth BioCare ASA Aktie

Kaufen

Verkaufen

Aktien-Sparplan anlegen Aktien-Sparplan anlegen

0,1100 EUR -0,0190 EUR -14,73 %

21:33:28

STU

1,40 NOK +0,09 NOK +6,87 %

22.07.2026

OSL

Hofseth BioCare ASA jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Smartphone

Marktkap.58,63 Mio. EUR

Div. Rendite0,00%

WKNA1JWL4

ISINNO0010598683

SymbolHOFBF

Hofseth BioCare ASA Aktien News

Sortieren:Datum Meistgelesen

23.05.25GlobeNewswireHofseth Biocare ASA: Annual General Meeting completed

16.05.25GlobeNewswireHofseth Biocare ASA: FIRST QUARTER 2025 FINANCIAL REPORT

05.05.25GlobeNewswireHofseth Biocare ASA: NESTLÉ GARDEN OF LIFE LAUNCHES HBC OMEGO® FULL SPECTRUM OMEGAS IN THE US

WerbungHofseth BioCare ASA-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

05.05.25GlobeNewswireHofseth Biocare ASA: SUCCESSFUL PLACEMENT OF NEW CHF-DENOMINATED UNSECURED BONDS

02.05.25GlobeNewswireHofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2025

11.04.25GlobeNewswireHofseth Biocare ASA: HBC ANNUAL REPORT 2024

10.03.25GlobeNewswireHofseth Biocare ASA: CONTEMPLATING UNSECURED BOND ISSUANCE

21.02.25GlobeNewswireHofseth Biocare ASA: HBC ACCELERATES IN HUMAN HEALTH AND PET NUTRITION THROUGH A STRATEGIC PARTNERSHIP WITH SYMRISE TO BUILD OUT BERKÅK, TRIPLING THE MANUFACTURING CAPACITY OF THE GROUP

20.02.25GlobeNewswireHofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION

14.02.25GlobeNewswireHofseth Biocare ASA: FOURTH QUARTER & FULL YEAR 2024 FINANCIAL REPORT

12.12.24GlobeNewswireHofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION

05.12.24GlobeNewswireHofseth Biocare ASA: Commences the project for a second hydrolysis plant in Norway to triple capacity

08.11.24GlobeNewswireHofseth Biocare ASA: THIRD QUARTER 2024 FINANCIAL REPORT

22.10.24GlobeNewswireHofseth Biocare ASA: CFO RESIGNATION

08.10.24GlobeNewswireHofseth Biocare ASA: HBC IMMUNOLOGY COMPLETES IN VIVO DRUG LEAD STUDIES FOR PROSTATE CANCER TREATMENT

23.08.24GlobeNewswireHofseth Biocare ASA: SECOND QUARTER AND HALF YEAR 2024 FINANCIAL REPORT

14.08.24GlobeNewswireHofseth Biocare ASA: GROUNDBREAKING STUDY REVEALS HOFSETH BIOCARE’S FULL SPECTRUM OMEGAS OMEGO SUPPORTS COVID-19 RECOVERY

02.07.24GlobeNewswireHofseth Biocare ASA: HBC discovers new drug candidate for asthma and transfers it to HBC Immunology Inc.

11.06.24GlobeNewswireHofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY

16.05.24GlobeNewswireHofseth Biocare ASA: FIRST QUARTER 2024 FINANCIAL REPORT

10.05.24GlobeNewswireHofseth Biocare ASA: Annual General Meeting completed

19.04.24GlobeNewswireHofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2024

19.04.24GlobeNewswireHofseth Biocare ASA: HBC ANNUAL REPORT 2023

05.04.24GlobeNewswireHofseth Biocare ASA: DISCLOSURE OF LARGE SHAREHOLDING

21.03.24GlobeNewswireHofseth Biocare ASA: UPDATED COMPANY PRESENTATION

14.03.24GlobeNewswireHofseth Biocare ASA: CHAIR KRISTIN FJELLBY GRUNG STEPS DOWN

09.02.24GlobeNewswireHofseth Biocare ASA: FOURTH QUARTER 2023 AND FULL YEAR FINANCIAL REPORT

06.02.24GlobeNewswireHofseth Biocare ASA: HBC Immunology Inc successfully completes first animal model of prostate cancer with FT-005 in combination with hormonal (anti-androgen) therapy demonstrating significant anti-tum

09.01.24GlobeNewswireHofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED

04.01.24GlobeNewswireHofseth Biocare ASA: EXTRAORDINARY GENERAL MEETING CONCLUDED

15.12.23GlobeNewswireHofseth Biocare ASA: EGM Notice Correction

14.12.23GlobeNewswireHofseth Biocare ASA: Notice of an extraordinary general meeting

13.12.23GlobeNewswireHofseth Biocare ASA: SIGNIFICANT NEW INVESTMENT OF NOK 144 MILLION FROM HOFSETH INTERNATIONAL INTO HBC

27.11.23GlobeNewswireHofseth Biocare ASA: DISCLOSURE OF LARGE SHAREHOLDING

27.11.23GlobeNewswireHofseth Biocare ASA: MANDATORY NOTIFICATION OF TRADE

10.11.23GlobeNewswireHofseth Biocare ASA: THIRD QUARTER 2023 FINANCIAL REPORT

25.08.23GlobeNewswireHofseth Biocare ASA: SECOND QUARTER 2023 FINANCIAL REPORT

17.08.23GlobeNewswireHofseth Biocare ASA: SUCCESSFULLY COMPLETED SEED ROUND CAPITAL RAISE IN HBC IMMUNOLOGY LLC AT $20M VALUATION FOR THE DEVELOPMENT OF A NEW PROSTATE CANCER CO-THERAPY

Hofseth BioCare ASA News

Hofseth BioCare ASA News: auf dieser Seite finden Sie alle Hofseth BioCare ASA News und Nachrichten zur Hofseth BioCare ASA Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Hofseth BioCare ASA News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Hofseth BioCare ASA News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.